Rocket Pharmaceuticals (RCKT) Cash from Operations (2014 - 2026)
Rocket Pharmaceuticals (RCKT) posted Cash from Operations of 45394000.0 for Q1 2026, down 30.29% sequentially from 34840000.0 in Q4 2025, and up 18.63% YoY from 38263851.27 in Q1 2025.
Powered by 
Analysis
Rocket Pharmaceuticals (RCKT) Cash from Operations (2014 - 2026) Analysis & Trends
Rocket Pharmaceuticals has reported Cash from Operations for 13 years, with the latest figure at 45394000.0 in Q1 2026.
- Quarterly Cash from Operations rose 18.63% year-over-year to 45394000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 179618000.0 (up 13.92% YoY) and the FY2025 annual result came in at 190014000.0, up 9.4% from the prior year.
- Cash from Operations retreated to 45394000.0 in Q1 2026 per RCKT's latest filing, from 34840000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 29339000.0 in Q4 2023 and troughed at 57560000.0 in Q1 2023.
- A 5-year average of 48128823.53 and a median of 50420000.0 in 2025 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2023: Cash from Operations sank 81.06% in 2022, then soared 47.63% in 2023.
- Over 5 years, Cash from Operations stood at 56021000.0 in 2022, then jumped by 47.63% to 29339000.0 in 2023, then plunged by 60.0% to 46942000.0 in 2024, then increased by 25.78% to 34840000.0 in 2025, then slumped by 30.29% to 45394000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 45394000.0, 34840000.0, and 50420000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Rocket Pharmaceuticals | 437.27 Mn | 437.27 Mn | - | -39.61 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -39.61 Mn |
| Mar 31, 2026 | -45.39 Mn |
| Dec 31, 2025 | -34.84 Mn |
| Sep 30, 2025 | -50.42 Mn |
| Jun 30, 2025 | -48.96 Mn |
| Mar 31, 2025 | -55.79 Mn |
| Dec 31, 2024 | -46.94 Mn |
| Sep 30, 2024 | -52.10 Mn |
| Jun 30, 2024 | -53.82 Mn |
| Mar 31, 2024 | -56.86 Mn |
| Dec 31, 2023 | -29.34 Mn |
| Sep 30, 2023 | -57.15 Mn |
| Jun 30, 2023 | -50.87 Mn |
| Mar 31, 2023 | -57.56 Mn |
| Dec 31, 2022 | -56.02 Mn |
| Sep 30, 2022 | -43.86 Mn |
| Jun 30, 2022 | -39.04 Mn |
| Mar 31, 2022 | -39.22 Mn |
| Dec 31, 2021 | -30.94 Mn |
| Sep 30, 2021 | -27.41 Mn |